Format

Send to

Choose Destination
Int J Mol Sci. 2012;13(5):6399-406. doi: 10.3390/ijms13056399. Epub 2012 May 23.

CD146 expression correlates with epithelial-mesenchymal transition markers and a poor prognosis in gastric cancer.

Author information

1
Department of General Surgery, Tongji Hospital of Tongji University, Shanghai 200065, China; E-Mail: Wenfangliu22@163.com.

Abstract

CD146 has been regarded as a novel potential therapeutic target for multiple cancers. The aim of the study was to investigate the expression of CD146 in gastric cancer and evaluate its clinical-pathological and prognostic significance. The expression of CD146 and three epithelial-mesenchymal transition (EMT)-related proteins (E-cadherin, β-catenin and vimentin) was examined in 144 gastric cancers by immunohistochemistry. Fifty-nine cases (41.0%) were defined as positive for CD146 expression. We found that CD146 expression correlated positively with lymph node involvement and a poor prognosis, and retained an independent prognostic factor for gastric cancer patients. Furthermore, positive expression of CD146 was strongly associated with loss of the epithelial marker E-cadherin and acquisition of the expression of the mesenchymal markers nuclear β-catenin and vimentin. These findings suggest that CD146 might promote EMT and progression in gastric cancer, and thus may be a potential therapeutic target for patients with gastric cancers.

KEYWORDS:

CD146; epithelial-mesenchymal transition; gastric cancer; immunohistochemistry; prognosis

PMID:
22754372
PMCID:
PMC3382746
DOI:
10.3390/ijms13056399
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
Loading ...
Support Center